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Readers are invited to use this article as a self- 
assessment exercise and to update their knowledge. 
ILLUSTRATIVE CASE HISTORY 
In 1995, a 46-year-old man presented with toxigenic 
diphtheria of the nasal cavity, pharynx, larynx and 
trachea. It was not known whether he had ever been 
immunized but, certainly, no booster immunization 
had been given during the previous 30 years. 
The patient was ill for 5 days before admission to 
hospital. The first symptom was a sore throat, but no 
medical advice was sought. After 2 days, his sore throat 
worsened, his temperature increased and he noticed 
swelling of the tonsillar region and a nasal discharge; 4 
days later, he had marked swelling of the neck. On  the 
night before admission, he was unable to sleep. On 
admission, he had a serosanguineous nasal discharge and 
inflammation of the palate, pharynx and tonsils, with a 
whitish membrane extending to the uvula. The larynx 
and vocal cords could not be visualized. There was 
hyperemia of the face and neck with soft tissue edema 
down to the level of the clavicles as well as tachypnea, 
tachycardia and arterial hypertension with respiratory 
distress, indicating respiratory obstruction and respira- 
tory insufficiency. A diagnosis of diphtheria was made. 
Throat and nasopharyngeal swabs including particles of 
membrane were taken for culture. These later yielded 
toxigenic Corynebucterium diphtheriae var gruois. 
Because the clinical picture strongly suggested 
diphtheria, specific treatment with antitoxin and 
antibiotics was initiated immediately. The skin test for 
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sensitivity to horse serum was negative. Diphtheria 
antitoxin (120,000 units) by intravenous infusion over 
60 min and intramuscular benzylpenicillin (30 mg/kg/ 
day) was administered. Central venous cannulation was 
performed for rapid administration of blood products 
and fluids. In addition, the patient was given corti- 
costeroids, diuretics and dopamine. 
Immediately after admission, oxygen was adminis- 
tered, but increasing tissue edema with airway obstruc- 
tion necessitated emergency airway management. 
Attempts at intubation by experienced personnel were 
unsuccessful and tracheostomy was performed, but the 
tracheostomy was only partially effective because of 
airway obstruction caused by expansion and sloughing 
of the tracheal and bronchial epithelium. Bronchoscopy 
with visual control and evacuation of membrane and 
other material produced considerable improvement in 
the airway. 
The systemic effects of diphtheria began to appear 
within a week. Severe myocarditis was diagnosed by 
physical examination, chest x-ray, electrocardiogram 
and laboratory data (elevations of serum creatine kinase, 
aspartate transaminase and lactate dehydrogenase). The 
main clinical problems were bradycardia and cardiac 
output disturbances. At the same time, the patient 
showed manifestations of neuritis with paralysis of 
the soft palate, the muscles of accommodation, the 
diaphragm and the limbs. Nutrition was maintained via 
nasogastric tube during the period of soft-palate 
paralysis, and mechanical ventilation was introduced at 
the stage of bulbar disturbance and diaphragm paralysis. 
Following termination of the acute infection, 
management of this patient resolved into adequate 
support of the vital functions, such as ventilation, 
nutrition and metabolism, and prevention of noso- 
comial infection. Six weeks after admission, mechanical 
ventilation was stopped, although a further 2 months 
was needed for the neurological signs to disappear. The 
patient was discharged from hospital 3 months after 
admission and, 6 months later, physical examination 
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revealed no abnord ty ,  in particular, no neurological 
signs. Nine months later, the patient visited hospital for 
a final physical examination and vaccination. 
MULTIPLE-CHOICE QUESTIONS 
Clinical and laboratory aspects of diphtheria 
In each ofthe numbered questions, at least one, and up to 
four, ofthe individual entries are correct. (The answers are at 
the end ofthis article.) 
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1. The following Corynebacterium species may 
produce diphtheria toxin 
C. diphtheriae var mitis True/False 
C. diphtheriae var beljinti True/False 
C. ulcerans Tme/False 
C. pseudotuberculosis (C. ovis) True/False 
C. pseudodiphthwiticum (C. hofmaniq True/False 
Laboratory diagnosis of diphtheria 
All potentially toxigenic corynebacteria 
produce cysteinase. True/False 
All potentially toxigenic corynebacteria 
produce pyrazinamidase. True/F&e 
Isolates biochemically confirmed as C. 
diphtheriae var gravis are always 
toxigenic. True/False 
Laboratory-acquired diphtheria has 
been reported. True/False 
Genotypic methods for toxigenicity 
testing [such as polymerase chain 
reaction (PCR) for the toxin gene] may 
completely replace phenotypic methods 
(such as the Elek test). True/False 
Diphtheria 
May occur in subjects who have 
received a full primary course of 
immunization and booster in 
childhood. True/False 
May be caused by C. ulcerans. True/False 
Should be considered in the clinical 
and laboratory diagnosis of skin ulcers 
in travellers returning fiom Asia and 
Africa. True/False 
Has an incubation period of not less 
than 10 days. True/False 
Soft-palate paralysis, a manifestation of 
diphtheritic neuritis, usually occurs 
during the first week of illness. True/False 
4. Diphtheria in Russia, the Ukraine and other 
newly independent states (NIS) of the former 
USSR 
a) These countries reported over 40,000 
cases of diphtheria to the World 
Health Organization (WHO) in 1994. True/False 
b) These countries reported approximately 
500 deaths due to diphtheria to the 
WHO in 1994. TrueIFalse 
diphtheria cases are predicted for 1995. True/False 
disease. TrueIFalse 
of the former USSR. True/False 
c) Between 100,000 and 200,000 
d) Is almost exclusively a childhood 
e) Has not spread beyond the borders 
5. Management of a case of suspected 
diphtheria 
Specific treatment should be delayed 
until laboratory confirmation is 
True/False available. 
Diphtheria antitoxin is a hyperimmune 
human immunoglobulin preparation. Tme/False 
Recommended antibiotic treatment 
regimens include penicillin or 
erythromycin. TrueIFalse 
Patients recovering fhrn diphtheria 
should be immunized with diphtheria 
toxoid before discharge f h m  hospital. 
Strict isolation of a case is not necessary 
afier 24 h of appropriate antibiotic 
therapy. True/False 
Tme/False 
Management of close contacts of a case of 
diphtheria 
Close contacts include a l l  staff and pupils 
of a school in which a case has been 
dagnosed. True/False 
Close contacts should be kept under 
daily health surveillance for 7 days fhrn 
the date of last contact with the 
patient. True/False 
In addition to nose and throat swabs 
h-om close contacts, any wounds or 
skin lesions should also be swabbed. 
Intramuscular benzathine penicillin is 
the recommended antibiotic of first 
choice for chemoprophylaxis in close 
contacts. TrueIFalse 
Booster immunization of close contacts 
is unnecessary if there is a documented 
history of dphtheria toxoid 
immunization in the preceding 5 years. True/False 
True/False 
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7. Diphtheria immunity and immunization 
a) The vast majority of adults in Western 
Europe are immune to diphtheria on 
the basis of serological surveys. 
b) Standard pediatric vaccine preparations 
are suitable for booster immunization 
in adults. True/False 
c) An antitoxin level of < 1 I U / d  in 
human serum, as determined by a 
toxin neutralization assay, indicates 
susceptibhty to infection. TrueIFalse 
by 1995, every country should achieve 
a 95% coverage for a booster dose of a 
diphtheria toxoid vaccine in school-age 
(5 to 14 years) children. 
e) High and sustained population coverage 
with diphtheria toxoid-containing 
vaccines has led to the virtual 
disappearance of toxigenic strains in 
some countries. True/False 
True/False 




Isolates of C. diphtheriae var mitis, intermedius and grauis, 
Corynebacterium ulcerans and Corynebacterium pseudo- 
tuberculosis may all secrete a potent toxin called 
diphtheria toxin [1,2] and, thus, may be referred to as 
potentially toxigenic corynebacteria. Toxigenic and 
non-toxigenic variants of the three potentially toxi- 
genic species and biotypes are distinguishable by in 
vitro and in vivo laboratory tests. The nitrate-negative 
variant of C. diphtheriae var mitis - C. diphtheriae var 
be@nti - is almost invariably non-toxigenic, although 
there has been one report of a toxin-producing isolate 
[3]. Diphtheria toxin is a potent polypeptide exotoxin 
of molecular weight 58 kDa comprising two hgments. 
Fragment B binds to specific receptors on susceptible 
cells whereas, following proteolync cleavage, fragment 
A (the 21 kDa N-terminal hgment) passes into the 
cytoplasm. Fragment A is an enzyme which catalyzes 
inactivation by adenosine diphosphate (ADP) ribo- 
sylation of the eukaryotic transfer ribonucleic acid 
(tRNA) translocase (elongation factor 2). At a minimal 
lethal dose of < 0.1 pg/kg body weight, diphtheria 
toxin is one of the most powerful bacterial toxins and 
is responsible for the clinical manifestations of the 
disease. Toxigenicity is correlated with infection of C. 
diphtheriae by a temperate phage, and lysogenization of 
a non-toxigenic strain with phage carrying the toxin 
gene will convert the organism into a toxigenic strain. 
The toxin is therefore, by definition, a phage-encoded 
protein [4]. 
Corynebacterium ulcerans is usually a commensal, 
and C. pseudotuberculosis is usually a pathogen, of farm 
animals, in particular, cattle and horses. Both species 
may produce diphtheria toxin [2] in addition to a 
dermonecrotic toxin. However, C. ulcerans has been 
associated with diphtheria-like illness in humans 
[5,6] whereas, although responsible for rare cases of 
suppurative granulomatous lymphadenitis [7], C. 
pseudotuberculosis has not. Exposure to infected animals 
or animal products, in particular, unpasteurized milk, 
appears to be necessary for infection, and person-to- 
person transmission of these species has not been 
described. In contrast, C. pseudodiphthen’ticum does not 
produce any toxins and is considered part of the normal 
human pharyngeal flora [8]. 
Question 2 
The principal role of the microbiology laboratory in 
the diagnosis of diphtheria is to provide simple, rapid 
and reliable methods to assist the clinicians in con- 
firming a clinical diagnosis. Microbiological diagnosis 
must be regarded as only complementary to, and not a 
substitute for, clinical diagnosis. Throat, nose and skin 
ulcer/wound swabs should be plated onto a non- 
selective blood agar and a selective medium containing 
potassium tellurite and lysed horse blood such as 
Hoyles medmm. Suspicious (black on tellurite-con- 
taining media) colonies should be Gram-stained and 
tested for catalase and urease production. Whereas C. 
diphtheriae biotypes are catalase-positive, urease-negative, 
gram-positive rods, C. ulcerans and C. pseudotuberculosis 
are urease-positive [9]. 
Two important tests for differentiating the 
potentially toxigenic corynebacteria from the non- 
toxigenic species involve detection of the enzymes 
pyrazinamidase and cysteinase. Cysteinase production is 
readily detected on Tinsdale medium: C. diphtheriae, C. 
ulcerans and C. pseudotuberculosis yield black colonies 
with a surrounding brown halo of diffused pigment 
whereas other corynebacteria may produce black 
colonies, but without a brown halo. It is advisable that 
each plate of Tinsdale medium be controlled by a 
clearly demarcated, small section of the plate that is 
heavily inoculated with a known cysteinase-positive 
strain. Pyrazinamidase production is detected by 
incubating a dense suspension of the organism in a 
sterile solution of pyrazinamide for a minimum of 4 h 
at 37OC and then adding ferrous ammonium sulfate 
solution. A negative result, absence of pyrazinamidase 
production, is indicated by a colorless to pale-yellow 
reaction and a positive result by the development of a 
deep orange-to-red colour. The potentially toxigenic 
species are all negative for pyrazinamidase production 
and all other corynebacteria are positive. As a negative 
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result is potentially of great significance, it is always 
advisable to set up a known pyrazinamidase-positive 
control strain, such as Corynebactetium xerosis (NCTC 
12078), at the same time [9,10]. 
The definitive identification of C .  diphtheriae to 
species and biotype level, and other corynebacteria to 
species level, relies on biochemical tests, fermentation 
of sugars, hydrolysis of urea and nitrate reduction in 
addition to the detection of toxigenicity. All biotypes 
of C. diphtheriae except be@nti are potentially toxigenic, 
but there is no absolute association between the biotype 
gravis and the ability to produce diphtheria toxin; 
consequently, it is necessary to subject all isolates to 
toxigenicity testing [9,10]. The Elek test is the only 
available method in the majority of laboratories. Given 
the immense public-health significance attached to the 
isolation of toxigenic C .  diphtheriae, any delay between 
isolation of a suspect organism and the results of 
toxigenicity tests can provoke great anxiety among 
laboratory staff, clinicians and public-health officials. 
The development of a rapid genotype test, using PCR 
for detection of the toxin gene, provides a rapid and 
useful assay of the potential for toxigenicity [l l] .  
However, a small number of isolates have been reported 
whch, although possessing the toxin gene, are unable 
to express the gene product [ l l] .  Thus, a definitive 
demonstration of toxigenicity s t i l l  requires some form 
of phenotype test. 
At least one case of laboratory-acquired diphtheria 
has been reported [12]. It is therefore recommended 
that laboratory workers who will or may handle 
toxigenic isolates should be proven to be immune by 
serological testing and receive booster immunization if 
necessary. In addition, it is reasonable to handle all work 
involving broth cultures or liquid suspensions of actual 
or potentially toxigenic strains in a class 1 biological 
safety cabinet. It should be remembered that the Elek 
test requires control with both strongly and weakly 
toxigenic C. diphtheriae control strains and, thus, even 
in the absence of toxigenic clinical isolates, laboratory 
workers are at risk. 
Full details of these methods are given in the 
Manual for the Laboratory Diagnosis of Diphtheria, 
published recently by the WHO Regional Office for 
Europe [9]. 
Question 3 
Immunity to diphtheria wanes over time and, 
consequently, the dsease may occur in adults with a full 
and documented history of childhood immunization. 
An illness consistent with a clinical diagnosis of 
diphtheria in a fully immunized subject should be 
regarded as such until proven otherwise. 
Corynebacteriym ulcerans may produce diphtheria 
toxin and, thus, may produce a clinical syndrome 
indistinguishable from disease due to toxigenic C.  
diphtheriae. Symptoms and signs of toxigenic C. ulcerans 
infection include exudative pharyngitis with toxic 
cardiac and neurological manifestations [5,6]. In suspect 
cases, diphtheria antitoxin should be administered. 
Cutaneous diphtheria should be considered in 
travellers returning to Europe fi-om countries in which 
diphtheria remains endemic, particularly the tropics. 
The usual presentation is of chronic non-healing ulcers 
with a dirty-grey membrane. Staphylococcus aureus and 
Streptococcus pyogenes are also often isolated fi-om these 
lesions. Cutaneous diphtheria does not usually lead to 
signs of intoxication, although such infections do 
induce high levels of circulating antitoxin and may act 
as natural immunizing events. Skin lesions may serve as 
a reservoir of toxigenic C. diphtheriae and may also 
contaminate the environment. Cutaneous diphtheria 
will induce throat infections in contacts at least as 
efficiently as pharyngeal infection [13]. 
The usual incubation period for respiratory tract 
diphtheria is 2 to 5 days. Contacts of a case should be 
kept under health surveillance for 7 days ftom the time 
of last contact with the patient [14]. Soft-palate 
paralysis, the most common neurological manifestation 
of diphtheria, usually develops during the third week 
of illness and is characterized by a nasal quality to the 
voice and nasal regurgitation. In addition, other neuro- 
logical manifestations include cranial and peripheral 
nerve palsies that are predominantly bilateral with 
motor, rather than sensory, involvement, and diaphrag- 
matic paralysis. Provided that the patient survives, the 
acute effects these neurological manifestations usually 
resolve completely. In most cases, the cardiac manifes- 
tations of diphtheria intoxication appear during the 
second week of illness. The more extensive the local 
lesion and the more delayed the institution of antitoxin 
therapy, the more frequently will myocarditis occur 
~ 4 1 .  
Question 4 
Although diphtheria was controlled for approximately 
30 years after the introduction of childhood vaccination 
with diphtheria toxoid in the late 1950s, epidemic 
diphtheria has reemerged in the NIS of the former 
USSR. The epidemic began in 1990 in the Russian 
Federation and spread to the Ukraine in 1991 and, 
during 1993 to 1994, to all 13 of the remaining NIS. 
Overall, reported cases of diphtheria in the NIS 
increased from 839 in 1989 to 47,802 in 1994. In 1994, 
a total of 1746 persons died; the case fatality rates 
ranged from 2.8 to 23% with 80% of these cases 
occurring within the Russian Federation [15]. 
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Epidemiological analysis indicates that 150,000 to 
200,000 cases with 7500 to 10,000 deaths will probably 
occur in 1995 if the emergency actions proposed to 
control the epidemic are unsuccessful [16]. 
Although the reasons for the epidemic are not fully 
understood, an important factor is the presence of large 
numbers of susceptible children and adults in the 
population which has enabled the spread of toxigenic 
C. diphtkeriae from foci of endemicity within the 
former USSR or from Russian military personnel 
returning from such areas in other countries. Spread 
of the organism may also be facilitated by crowding 
and population migration. The increased number of 
susceptible children in the NIS is probably the result of 
a combination of low vaccination coverage in many 
areas and inadequate primary vaccination courses [ 151. 
In Russia in 1993, the rates of disease per 100,000 
population did not differ between adults and children 
(age 0 to 14 years, 12/100,000 population; age > 14 
years, 9/100,000 population; all ages, 10/100,000 
population) [ 141. 
During the past 3 years, Finland, Germany, 
Norway and Poland have registered cases imported 
from countries of the former USSR [14]. Two citizens 
of the United States contracted the disease after visiting 
or working in the Russian Federation [17]. 
Question 5 
Specific treatment with antitoxin and antibiotics should 
be commenced immediately if diphtheria is suspected 
on clinical grounds. In most countries of Western 
Europe, where diphtheria is extremely rare, suspect 
cases or their close contacts are very likely to have a 
relevant travel history and this should always be sought 
in such cases. The drugs of choice are penicillin and 
erythromycin by injection until the patient is able to 
swallow comfortably. Antibiotic treatment is necessary 
to eliminate the organism and prevent spread; it is not 
a substitute for antitoxin treatment. Under no circum- 
stances should specific (antitoxin) treatment be delayed 
pending laboratory confirmation of toxigenicity if the 
clinical examination and patient history are suggestive 
of hphtheria. 
Diphtheria antitoxin is a hyperimmune serum 
produced in horses. Before antitoxin is administered, 
the patient should be tested for sensitivity to horse 
serum and, if necessary, desensitized. The dose of anti- 
toxin depends on the site and extent of the diphtheritic 
membrane, degree of toxicity and duration of illness, 
and is typically 20,000 to 40,000 units by intramuscular 
or intravenous injection for pharyngeal or laryngeal 
diphtheria. However, there are manufacturer and 
national health authority variations in dosage recom- 
mendations, and prescribers should seek expert advice. 
Epinephrine should be readily available whenever 
antitoxin is administered in case of acute anaphylaxis. 
Antitoxin only neutralizes circulating toxin that is not 
yet bound to tissues and, thus, prompt administration 
is critical. Delayed administration increases the risk of 
late effects such as myocarditis and neuritis. 
AU cases (suspected or confirmed) should be 
reported to the local health authority without delay, 
and advice from the national communicable disease 
surveillance unit and the reference laboratory sought 
immediately. The patient should be nursed in strict 
isolation until bacteriological clearance has been 
confirmed by negative cultures of nasopharyngeal and 
throat swabs obtained at least 24 h after completing 
treatment. Clinical diphtheria does not necessarily 
confer natural immunity and, therefore, patients with 
diphtheria should be vaccinated before hscharge from 
hospital. Previously unvaccinated individuals should 
immediately receive a dose of diphtheria toxoid- 
containing vaccine (preferably Td) and, later, complete 
a full primary course of no fewer than three doses. 
Partially vaccinated subjects should complete the 
primary course according to the national recom- 
mendations; fully vaccinated persons should receive a 
booster dose. More detailed descriptions of the 
procedures involved are given in the WHO Manual for 
the Management and Control of Diphtheria [14] and 
by Farizo and colleagues [18]. 
Question 6 
Anyone who has been in close contact with a case of 
diphtheria caused by toxigenic C. dipktkeriae in the 
previous 7 days should be considered at risk. Contacts 
of cases due to non-toxigenic C. diphtheriae are not at 
risk. Close contacts include: school-classroom contacts; 
household contacts; friends, relatives and caretakers 
who regularly visit the home; kissing/sexual contacts; 
those who share the same room at work; and health 
workers exposed to oropharyngeal secretions from the 
patient [ 141. 
Close contacts should be clinically assessed for 
symptoms and signs of diphtheria, including cutaneous 
diphtheria, and kept under surveillance for 7 days 
from the time of the last contact with the patient. In 
addition, a travel history should be obtained from 
contacts as they may be the source of the patient’s 
infection. The management of close contacts includes 
clinical surveillance, bacteriological investigation (nasal, 
pharyngeal and wound or other skin lesion swabs), 
antibiotic therapy and immunization. Carriage rates of 
toxigenic C. diphtheriae among household contacts may 
be as high as 25%. If a positive culture is obtained from 
a close contact, the carrier’s close contacts should be 
identified and the preventative measures described for 
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close contacts of a patient initiated. Recommended 
chemoprophylaxis regimens include intramuscular 
benzathine penicillin or a 7- to 10-day course of oral 
erythromycin. However, although the latter is easier to 
administer, it is not routinely recommended because of 
the risk of poor compliance. Repeat culture should be 
undertaken 2 weeks after completion of the antibiotic 
course to ensure eradlcation of the organism. 
Close contacts who have received fewer than three 
doses of diphtheria toxoid in the past or whose 
immunization status is unknown should be given an 
immediate booster dose of dlphtheria toxoid-contain- 
ing vaccine, followed by completion of the hl l  
immunization series according to the nationally 
recommended schedule. Contacts who have had three 
doses of vaccines in the past should also receive an 
immediate booster dose. If the last dose was given 
during the previous 12 months, a booster dose is 
unnecessary [ 141. 
Question 7 
Serological surveys have revealed that there is a 
significant ‘gap’ in adult immunity to diphtheria toxin. 
A recent study &om the UK of 1000 blood donors, 
aged 20 to 59 years, showed that, overall, 37.6% 
were susceptible (antitoxin levels < 0.01 IU/mL) to 
diphtheria, 31.5% had basic protection (antitoxin levels 
0.01 to 0.09 IU/mL) and 30.9% were hlly protected 
(antitoxin levels > 0.1 IU/mL.). In this study, there was 
a significant trend of decreasing immunity with 
increasing age and, among those aged 50 to 59 years, 
53% were susceptible [19]. S i d a r  results have been 
obtained in serological surveys fiom other Western 
European countries and the United States. 
Pediatric diphtheria toxoid-containing vaccines are 
not suitable for booster immunization of adults mainly 
because such vaccines contain large antigen doses, 
which are necessary for priming the immune response. 
Exact details of vaccine composition may vary among 
manufacturers and depend on national recommen- 
dations. However, typical pediatric preparations 
contain 30 IU of diphtheria toxoid whereas adult 
booster preparations usually contain 4 IU of diphtheria 
toxoid. Use of the larger (pediatric) antigen dose for 
booster immunization in adults and adolescents is more 
likely to induce adverse reactions and therefore should 
be avoided. 
For epidemiological purposes, the minimum 
protective level is considered to be 0.01 IU/mL. of 
diphtheria antitoxin in a serum sample. The higher 
level of 0.1 IU/mL is desirable for individual protection 
but, in the majority of subjects, such levels are not 
maintained over a long period of time. An antitoxin 
level greater than 1 IU/mL. is regarded as indicating 
long-term protection (91. Periodic serological surveys 
are essential with particular emphasis on adults over the 
age of 30 years whose immunity has not been boosted 
by natural infection. 
The targets proposed by the WHO are that each 
region should achieve 95% coverage with both a 
primary immunization series in children by 2 years of 
age and a booster dose of diphtheria toxoid-containing 
vaccine in school-age children [14]. As part of the 
WHO strategy for prevention and control of diphtheria 
in Europe, it has been proposed that countries affected 
by a resurgence of diphtheria shodd institute mass 
immunization with diphtheria toxoid-containing 
vaccines (preferably Td) for certain ‘high-risk‘ groups, 
including adults over 25 years of age who are healthcare 
workers, members of the armed forces, employees of 
transportation services with fkquent public contact, 
teachers, kindergarten and creche staf€, alcoholics and 
among the homeless [20]. 
In many countries of Western Europe with 
effective immunization programs, circulation of 
toxigenic strains of C. diphtheriae has virtually ceased for 
reasons that are not entirely clear and much debated. In 
the absence of circulating toxigenic C. diphtheriae, 
‘natural immunization’ of populations, including 
boosting the immune response by exposure to such 
strains, can no longer take place. Thus, it may be 
necessary to consider a wider and more systematic 
application of diphtheria booster immunization among 
adults to ensure adequate hture ‘herd’ immunity and 
to avoid the potential reemergence of epidemic 
diphtheria in the 1990s that has already been realized 
in countries of the former USSR. 
Answers to the multiple-choice questions 
41: a. True; b. True ; c. True; d. True; e. False 
42: a. True; b. False; c. False; d. True; e. False 
43: a. True; b. True; c. True; d. False; e. False 
44: a. True; b. False; c. True; d. False; e. False 
4 5 :  a. False; b. False; c. True; d. True; e. False 
46: a. False; b. True; c. True; d. True; e. False 
47: a. False; b. False; c. False; d. True; e. True 
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